ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
ERYTECH (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Second Quarter 2017 conference call and webcast on Tuesday, September 12, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 54851684#:
|USA: +1 6467224907||United-Kingdom: +44 2030432440|
|Switzerland: +41 225809022||Germany: +49 69222229031|
|France: +33 172001510||Belgium: +32 24029640|
|Sweden: +46 850334664||Finland: +358 942599700|
|Netherlands: +31 107138194||Spain: +34 914142021|
The webcast can be followed live online via the link:
An archived replay of the call will be available for 90 days by dialing (US & Canada): +1 877 64 230 18, (UK): +44(0) 203 367 9460, (France): +33(0)1 72 00 15 00, (Spain): +34 917896320, Conference ID # 310581#
An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com.
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH, which plans to pursue regulatory approvals for its lead product candidate, eryaspase, also known under the trade name GRASPA®, reported positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy. ERYTECH believes that eryaspase also has potential as a treatment approach in solid tumors and has completed a Phase 1 study and a Phase 2b clinical trial in France, evaluating eryaspase in patients with second line metastatic pancreatic cancer.
Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma. ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform to develop cancer immunotherapies and enzyme replacement therapies.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Chairman and CEO
CFO and COO
+33 4 78 74 44 38
The Ruth Group
Lee Roth, +1 646 536 7012
Kirsten Thomas, +1 508 280 6592
+33 1 44 71 98 52
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Bigelow Space Operations Announces Partnership with CASIS to Fly Payloads to the International Space Station21.2.2018 03:18 | Tiedote
Bigelow Space Operations (BSO) is proud to announce a partnership with the Center for the Advancement of Science in Space (CASIS), manager of the International Space Station (ISS) U.S. National Laboratory. BSO is officially a user of the ISS National Lab, and will be facilitating the integration of payloads for commercial, academic and government customers. In this capacity, BSO intends to contract with other payload integrating companies where we not only can help those companies to develop their dynamic futures for themselves and their successful clients extending beyond ISS operations, but to also offer ourselves as a customer and understand how to help CASIS. This may be important if CASIS is to someday enable usage of B330 stations. BSO’s mandate is to promote the services of the ISS National Lab, promote other payload facilitating companies and to develop new relationships for the ISS and Bigelow Aerospace stations. BSO will kick off this through a recently awarded CASIS partner
Bigelow Aerospace Announces the Creation of Bigelow Space Operations21.2.2018 01:00 | Tiedote
Bigelow Aerospace is excited to introduce Bigelow Space Operations (BSO), a new commercial space company that is the sales, operational and customer service company that manages and operates space stations developed by Bigelow Aerospace. With the two launches of B330-1 and B330-2 expected in 2021, the time is now in 2018 to begin BSO activity. These single structures that house humans on a permanent basis will be the largest, most complex structures ever known as stations for human use in space. The customers that B330 will seek to accommodate will be very diverse. Bigelow Space Operations has a mission to market and operate these and other space stations including future generations developed by Bigelow Aerospace that are so capable, so diverse and so large that they can accommodate virtually unlimited use almost anywhere. Over time, Bigelow Aerospace will manufacture a single station, launched on a single rocket that will contain over 2.4 times the pressurized volume of the entire In
Andersen Tax & Legal Launches in Egypt20.2.2018 17:30 | Tiedote
The Andersen name launches in Egypt this week as Maher Milad Iskander and Co., an Egyptian tax and legal firm based in Cairo, formally adopts the name Andersen Tax & Legal. Maher Milad Iskander and Co. became a collaborating firm of Andersen Global in July of 2017 and is one of three that have become member firms and adopted the Andersen name thus far in 2018. Maher Milad Iskander, Managing Partner of Andersen Tax & Legal in Egypt, said, “Andersen Global’s strategy of focusing on outstanding tax and legal services will provide us with many advantages and will allow us to even better serve our cross-border clientele. We are looking forward to our continued work with the Andersen team and to seamlessly providing innovative and client-focused solutions on a global level through our colleagues around the world.” “Egypt is considered to be one of the highest growing markets in the world and our adoption of the Andersen name in Egypt has come at the perfect time,” added Global Chairman and A
First Dedicated Esports Apparel Brand H4X.gg Unveils Its Debut Line of Performance Gear and Streetwear, Partners with ESL and DreamHack20.2.2018 17:00 | Tiedote
Esports apparel and gear company Moniker, Inc. ("Moniker") has introduced the first esports lifestyle brand H4X.gg (pronounced “hacks”) with high quality performance wear and casual streetwear for esports athletes and fans. H4X.gg has partnered with ESL, the world’s largest esports company, and DreamHack, the world’s largest digital festival, to become the official apparel supplier of ESL One, Intel® Extreme Masters, DreamHack Open, DreamHack Masters and DreamLeague 2018, kicking off with ESL One in Katowice, Poland on February 24-25. "We are very happy to partner with the first dedicated esports apparel brand designed specifically for fans and players,” said Bernhard Mogk, SVP Global Sales & Business Development at ESL. “We’re incredibly excited to debut the line of performance gear at ESL One Katowice this month and roll out the entire line at future ESL events throughout 2018.” The H4X.gg line was developed by passionate gamers and esports industry veterans at BITKRAFT Esports Ventu
Proposals of the Supervisory Board to Be Submitted to the Annual General Shareholders' Meeting of Sartorius AG20.2.2018 17:00 | Tiedote
At today’s meeting, the Supervisory Board of Sartorius AG, approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on April 5, 2018, to raise dividends to 0.51 euros per preference share and 0.50 euros per ordinary share. Prior-year dividends were 0.46 euros and 0.45 euros per preference share and per ordinary share, respectively. Therefore, the total amount disbursed under this proposal would increase by 11.0% to 34.5 million euros from 31.1 million euros a year earlier. In addition, the Supervisory Board will submit a proposal to the Annual General Shareholders’ Meeting to elect Dr. Guido Oelkers to the Supervisory Board as a representative of the shareholders. Guido Oelkers has already been a member of this board since November 2017. He was appointed by court order after Supervisory Board member Professor Arnold Picot, Ph.D., had passed away. Guido Oelkers, who was born in 1965 and holds a university degree in business administr
ETECSA Enhances Connectivity to the Rest of the World with SES Networks20.2.2018 17:00 | Tiedote
Cubans and visitors to Cuba will have additional access to reliable and uninterrupted connectivity throughout the main island of Cuba as ETECSA, Cuba’s national telecommunications operator, signed a deal with SES Networks for satellite services, SES announced today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180220005894/en/ ETECSA Enhances Connectivity to the Rest of the World with SES Networks (Photo: Business Wire) SES Networks will augment ETECSA’s existing terrestrial infrastructure with its high-performance fibre-like medium earth orbit (MEO) capacity and improve connectivity for end-customers of the Cuban operator. “By working with SES Networks, we are ensuring that our customers across the main island will have a new way to access high-performing Internet at all times through this innovative satellite system. Our collaboration with SES Networks highlights ETECSA’s mission of providing telecommunications services t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme